Supplementary Figures 1-12 from A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination

Abstract

Listen

Translate article

<p>Supplementary Figure 1. Expression of CXCR4 by immunofluorescence and of mouse Cxcr4 and human CXCR7 by RT-PCR; Supplementary Figure 2. Decrease in number of CXCR4-positive cells arising from AMD3100 treatment; Supplementary Figure 3. Absence of effect of AMD3100 on fibrosis, necrosis and proliferation; Supplementary Figure 4. Inhibition of angiogenesis by AMD3100; Supplementary Figure 5. Cytometric analysis of CTCs in blood of OVA17 implanted animals; Supplementary Figure 6. Cytokeratin 19 mRNA analysis in blood from ovarian carcinoma patients; Supplementary Figure 7. CXCR4 immunostaining in SKOV-3 tumors; Supplementary Figure 8. Absence of effect of shCXCR4 expression in SKOV-3 cells proliferation and viability, but decrease of angiogenesis in tumors; Supplementary Figure 9. Cytometric analysis of CTCs in blood of SKOV-3-sh control and SKOV-3-shCXCR4 863 inoculated animals; Supplementary Figure 10. CXCR4 inhibition by shRNA expression blocks Src and ERKs activation; Supplementary Figure 11. Cytometric analysis of GFP and CXCR4 expression in cells isolated from SKOV-3 xenografts; Supplementary Figure 12. CXCR4 and E-cadherin expression in consecutive sections of OVA17 tumors</p>